– Two posters describe features of Catamaran’s CAR-NK platform designed to overcome the immunosuppressive effects of the solid tumor microenvironment –CAMBRIDGE, Mass. (BUSINESS WIRE) Catamaran Bio, Inc., a biotechnology company developing off‑the-shelf chimeric antigen receptor (CAR)-NK cell therapies to treat ca.
Stock Market | Daily Herald dailyherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailyherald.com Daily Mail and Mail on Sunday newspapers.
Astellas and MBC BioLabs Announce Future Innovator Prize Winners - Helping Biotech Start-ups Accelerate Early Research Efforts ycharts.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ycharts.com Daily Mail and Mail on Sunday newspapers.